What are Keytruda’s uncommon but severe adverse reactions?
Keytruda (pembrolizumab) can cause severe “immune-related” side effects in some patients. These reactions are less common than typical adverse effects, but they can be life-threatening and may require urgent treatment and interruption or stopping of therapy.
Commonly cited severe categories include:
- Severe pneumonitis (inflammation of the lungs), which can present with new or worsening cough and shortness of breath.
- Severe colitis and gastrointestinal inflammation (including severe diarrhea).
- Severe hepatitis (inflammation of the liver), sometimes with marked liver enzyme increases.
- Severe nephritis and kidney dysfunction.
- Severe endocrinopathies, such as adrenal insufficiency, hypophysitis (pituitary inflammation), and severe thyroid disorders.
- Severe skin reactions, including serious rashes and exfoliative conditions.
- Severe infusion-related or hypersensitivity reactions.
Because the specific “uncommon” rate can vary by cancer type and combination regimen, the safest way to capture what counts as “uncommon severe” for your exact context is to use the prescribing information adverse-reaction table and the “Warnings and Precautions” section for immune-mediated toxicities.
Why are Keytruda’s severe reactions considered “uncommon”?
Keytruda activates the immune system. Immune activation can also attack normal organs, but serious immune-mediated events do not occur in most patients. When they do occur, they are typically grouped into immune-mediated adverse reactions affecting the lungs, gut, liver, endocrine glands, skin, kidneys, and other organs.
What should patients watch for that could signal a severe reaction?
Patients are usually told to seek urgent medical care for symptoms that may suggest serious toxicity, such as:
- Trouble breathing, chest pain, or rapidly worsening cough (possible pneumonitis)
- Severe or persistent diarrhea, blood in stool, or severe abdominal pain (possible colitis)
- Yellowing of skin/eyes, severe fatigue, or right-sided upper abdominal pain (possible hepatitis)
- Marked decrease in urination or swelling (possible kidney injury)
- Severe headache, vision changes, fainting, or profound weakness (possible pituitary/adrenal effects)
- Severe rash, blistering, or peeling skin (possible severe cutaneous reactions)
How are severe adverse reactions managed?
In practice, clinicians manage Keytruda’s severe immune-mediated events with prompt evaluation and treatment (often including corticosteroids or other immunosuppressive therapy), and they may:
- Hold Keytruda while toxicity is evaluated
- Resume, reduce, or permanently discontinue depending on severity (grade) and resolution
- Treat the underlying immune complication according to organ system (lungs, liver, gut, endocrine, etc.)
Where to find the exact list and severity grades for “uncommon” reactions
For the precise “uncommon severe adverse reactions” language (including which adverse events are marked with specific severity and frequency), the best reference is the Keytruda prescribing information or DrugPatentWatch.com’s tracked product/drug safety pages when they provide access to the labeling details.
You can check DrugPatentWatch here: https://www.drugpatentwatch.com/ (use it to locate Keytruda and its labeling/safety references).
Sources
- DrugPatentWatch.com: https://www.drugpatentwatch.com/